Yanan Jiang

Changhongjie, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 21 publications

Correction: Neoadjuvant and/or adjuvant immune checkpoint inhibitors combined with chemotherapy for locally advanced resectable penile squamous cell carcinoma.

Correction: Neoadjuvant and/or adjuvant immune checkpoint inhibitors combined with chemotherapy for locally advanced resectable penile squamous cell carcinoma.

Journal: Frontiers in immunology

Published: April 22, 2026

Neoadjuvant and/or adjuvant immune checkpoint inhibitors combined with chemotherapy for locally advanced resectable penile squamous cell carcinoma.

Neoadjuvant and/or adjuvant immune checkpoint inhibitors combined with chemotherapy for locally advanced resectable penile squamous cell carcinoma.

Journal: Frontiers in immunology

Published: October 24, 2025

Synergistic Antitumor Activity of HAT Inhibitor A485 and XPO1 Inhibitor KPT8602 in Multiple Myeloma.

Synergistic Antitumor Activity of HAT Inhibitor A485 and XPO1 Inhibitor KPT8602 in Multiple Myeloma.

Journal: Cancer medicine

Published: October 11, 2025

Programmed-Cell-Death-Related Signature Reveals Immune Microenvironment Characteristics and Predicts Therapeutic Response in Diffuse Large B Cell Lymphoma.

Programmed-Cell-Death-Related Signature Reveals Immune Microenvironment Characteristics and Predicts Therapeutic Response in Diffuse Large B Cell Lymphoma.

Journal: Biomedicines

Published: August 13, 2025

High-dose vitamin C potently induces apoptosis in acute lymphoblastic leukemia by activating ER stress response.

High-dose vitamin C potently induces apoptosis in acute lymphoblastic leukemia by activating ER stress response.

Journal: Human & experimental toxicology

Published: May 30, 2025

Targeting EP300 in diffuse large b-cell lymphoma: efficacy of A485 and synergistic effects with XPO1 inhibition.

Targeting EP300 in diffuse large b-cell lymphoma: efficacy of A485 and synergistic effects with XPO1 inhibition.

Journal: BMC cancer

Published: January 21, 2025

SUMOylation-related genes define prognostic subtypes in stomach adenocarcinoma: integrating single-cell analysis and machine learning analyses.

SUMOylation-related genes define prognostic subtypes in stomach adenocarcinoma: integrating single-cell analysis and machine learning analyses.

Journal: Frontiers in immunology

Published: November 13, 2024

A Cuproptosis-related lncRNA Signature for Prognostic Stratification and Immunotherapeutic Implications in Lung Adenocarcinoma.

A Cuproptosis-related lncRNA Signature for Prognostic Stratification and Immunotherapeutic Implications in Lung Adenocarcinoma.

Journal: Current molecular medicine

Published: October 25, 2024

The epigenetic regulators EP300/CREBBP represent promising therapeutic targets in MLL-rearranged acute myeloid leukemia.

The epigenetic regulators EP300/CREBBP represent promising therapeutic targets in MLL-rearranged acute myeloid leukemia.

Journal: Cell death discovery

Published: January 10, 2024

Comparison of blinatumomab and CAR T-cell therapy in relapsed/refractory acute lymphoblastic leukemia: a systematic review and meta-analysis.

Comparison of blinatumomab and CAR T-cell therapy in relapsed/refractory acute lymphoblastic leukemia: a systematic review and meta-analysis.

Journal: Expert review of hematology

Published: December 22, 2023

Corrigendum: Identification of microtube-associated biomarkers in diffuse large B-cell lymphoma and prognosis prediction.

Corrigendum: Identification of microtube-associated biomarkers in diffuse large B-cell lymphoma and prognosis prediction.

Journal: Frontiers in genetics

Published: March 05, 2023

Prognostic Significance of Ribosome-related Genes Signature in Diffuse Large B Cell Lymphoma.

Prognostic Significance of Ribosome-related Genes Signature in Diffuse Large B Cell Lymphoma.

Journal: Journal of Cancer

Published: November 16, 2022

Showing 1-12 of 21

Last Updated: 09/26/2026